can semaglutide cause ketoacidosis Type 1 on a GLP-1 Drug? Watch for Hypoglycemia and DKA Risk factors of ketoacidosis 1.

GLP-1 Market Share, By Indication, 2025 (%) The obesity and weight management segment held a 28% share of the market in 2025 and is expected to grow at the fastest CAGR of 18.6% during the projection period

You may notice early weight loss during the first weeks of using semaglutide

These variations dont necessarily indicate quality problems

Although clinical trials show similar adverse effects (AEs) with both formulationsmost commonly GI symptoms such as nausea and vomitingexperts suggest these may be more pronounced with the oral option because of its administration method

Participants who remained on 2.4 mg semaglutide for 104 weeks maintained their weight loss throughout